Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • RETRACTED: Clinical research o...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

RETRACTED: Clinical research on the efficacy of self-made sichongsan in combination with gefitinib on NSCLC patients with EGFR mutation

Bibliographic Details
Published in:European Journal of Inflammation
Main Authors: Yibo Zhao, Yu Dong, Shu Xing, Xueqi Fu
Format: Article
Language:English
Published: SAGE Publishing 2018-06-01
Online Access:https://doi.org/10.1177/2058739218782228
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1177/2058739218782228

Similar Items

  • First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation
    by: Yanjuan Xiong, et al.
    Published: (2024-10-01)
  • RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC
    by: Makoto Nishio, MD, PhD, et al.
    Published: (2022-04-01)
  • Ginsenoside Rg3 Adjunctively Increases the Efficacy of Gefitinib Against NSCLC by Regulating EGFR Copy Number
    by: Xinyi Lv, et al.
    Published: (2025-07-01)
  • The targeting of AKR1C1 synergizes with gefitinib via the STAT3 signaling pathway in EGFR-mutated NSCLC
    by: Linlin Chang, et al.
    Published: (2025-11-01)
  • Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
    by: Bin Zou, et al.
    Published: (2018-03-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs